A new genetic disorder in mitochondrial fatty acid β-oxidation: ACAD9 deficiency

M. He, S. L. Rutledge, D. R. Kelly, C. A. Palmer, G. Murdoch, N. Majumder, R. D. Nicholls, Z. Pei, Paul A Watkins, Jerry Vockley

Research output: Contribution to journalArticle

Abstract

The acyl-CoA dehydrogenases are a family of multimeric flavoenzymes that catalyze the α,β-dehydrogenation of acyl-CoA esters in fatty acid β-oxidation and amino acid catabolism. Genetic defects have been identified in most of the acyl-CoA dehydrogenases in humans. Acyl-CoA dehydrogenase 9 (ACAD9) is a recently identified acyl-CoA dehydrogenase that demonstrates maximum activity with unsaturated long-chain acyl-CoAs. We now report three cases of ACAD9 deficiency. Patient 1 was a 14-year-old, previously healthy boy who died of a Reye-like episode and cerebellar stroke triggered by a mild viral illness and ingestion of aspirin. Patient 2 was a 10-year-old girl who first presented at age 4 mo with recurrent episodes of acute liver dysfunction and hypoglycemia, with otherwise minor illnesses. Patient 3 was a 4.5-year-old girl who died of cardiomyopathy and whose sibling also died of cardiomyopathy at age 21 mo. Mild chronic neurologic dysfunction was reported in all three patients. Defects in ACAD9 mRNA were identified in the first two patients, and all patients manifested marked defects in ACAD9 protein. Despite a significant overlap of substrate specificity, it appears that ACAD9 and very-long-chain acyl-CoA dehydrogenase are unable to compensate for each other in patients with either deficiency. Studies of the tissue distribution and gene regulation of ACAD9 and very-long-chain acyl-CoA dehydrogenase identify the presence of two independently regulated functional pathways for long-chain fat metabolism, indicating that these two enzymes are likely to be involved in different physiological functions.

Original languageEnglish (US)
Pages (from-to)87-103
Number of pages17
JournalAmerican Journal of Human Genetics
Volume81
Issue number1
DOIs
StatePublished - Jul 2007

Fingerprint

Acyl-CoA Dehydrogenase
Inborn Genetic Diseases
Fatty Acids
Acyl-CoA Dehydrogenases
Long-Chain Acyl-CoA Dehydrogenase
Cardiomyopathies
Acyl Coenzyme A
Tissue Distribution
Substrate Specificity
Neurologic Manifestations
Hypoglycemia
Aspirin
Liver Diseases
Siblings
Esters
Eating
Stroke
Fats
Amino Acids
Messenger RNA

ASJC Scopus subject areas

  • Genetics

Cite this

He, M., Rutledge, S. L., Kelly, D. R., Palmer, C. A., Murdoch, G., Majumder, N., ... Vockley, J. (2007). A new genetic disorder in mitochondrial fatty acid β-oxidation: ACAD9 deficiency. American Journal of Human Genetics, 81(1), 87-103. https://doi.org/10.1086/519219

A new genetic disorder in mitochondrial fatty acid β-oxidation : ACAD9 deficiency. / He, M.; Rutledge, S. L.; Kelly, D. R.; Palmer, C. A.; Murdoch, G.; Majumder, N.; Nicholls, R. D.; Pei, Z.; Watkins, Paul A; Vockley, Jerry.

In: American Journal of Human Genetics, Vol. 81, No. 1, 07.2007, p. 87-103.

Research output: Contribution to journalArticle

He, M, Rutledge, SL, Kelly, DR, Palmer, CA, Murdoch, G, Majumder, N, Nicholls, RD, Pei, Z, Watkins, PA & Vockley, J 2007, 'A new genetic disorder in mitochondrial fatty acid β-oxidation: ACAD9 deficiency', American Journal of Human Genetics, vol. 81, no. 1, pp. 87-103. https://doi.org/10.1086/519219
He, M. ; Rutledge, S. L. ; Kelly, D. R. ; Palmer, C. A. ; Murdoch, G. ; Majumder, N. ; Nicholls, R. D. ; Pei, Z. ; Watkins, Paul A ; Vockley, Jerry. / A new genetic disorder in mitochondrial fatty acid β-oxidation : ACAD9 deficiency. In: American Journal of Human Genetics. 2007 ; Vol. 81, No. 1. pp. 87-103.
@article{43092015344e4366bb3c510e6b01c7c5,
title = "A new genetic disorder in mitochondrial fatty acid β-oxidation: ACAD9 deficiency",
abstract = "The acyl-CoA dehydrogenases are a family of multimeric flavoenzymes that catalyze the α,β-dehydrogenation of acyl-CoA esters in fatty acid β-oxidation and amino acid catabolism. Genetic defects have been identified in most of the acyl-CoA dehydrogenases in humans. Acyl-CoA dehydrogenase 9 (ACAD9) is a recently identified acyl-CoA dehydrogenase that demonstrates maximum activity with unsaturated long-chain acyl-CoAs. We now report three cases of ACAD9 deficiency. Patient 1 was a 14-year-old, previously healthy boy who died of a Reye-like episode and cerebellar stroke triggered by a mild viral illness and ingestion of aspirin. Patient 2 was a 10-year-old girl who first presented at age 4 mo with recurrent episodes of acute liver dysfunction and hypoglycemia, with otherwise minor illnesses. Patient 3 was a 4.5-year-old girl who died of cardiomyopathy and whose sibling also died of cardiomyopathy at age 21 mo. Mild chronic neurologic dysfunction was reported in all three patients. Defects in ACAD9 mRNA were identified in the first two patients, and all patients manifested marked defects in ACAD9 protein. Despite a significant overlap of substrate specificity, it appears that ACAD9 and very-long-chain acyl-CoA dehydrogenase are unable to compensate for each other in patients with either deficiency. Studies of the tissue distribution and gene regulation of ACAD9 and very-long-chain acyl-CoA dehydrogenase identify the presence of two independently regulated functional pathways for long-chain fat metabolism, indicating that these two enzymes are likely to be involved in different physiological functions.",
author = "M. He and Rutledge, {S. L.} and Kelly, {D. R.} and Palmer, {C. A.} and G. Murdoch and N. Majumder and Nicholls, {R. D.} and Z. Pei and Watkins, {Paul A} and Jerry Vockley",
year = "2007",
month = "7",
doi = "10.1086/519219",
language = "English (US)",
volume = "81",
pages = "87--103",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - A new genetic disorder in mitochondrial fatty acid β-oxidation

T2 - ACAD9 deficiency

AU - He, M.

AU - Rutledge, S. L.

AU - Kelly, D. R.

AU - Palmer, C. A.

AU - Murdoch, G.

AU - Majumder, N.

AU - Nicholls, R. D.

AU - Pei, Z.

AU - Watkins, Paul A

AU - Vockley, Jerry

PY - 2007/7

Y1 - 2007/7

N2 - The acyl-CoA dehydrogenases are a family of multimeric flavoenzymes that catalyze the α,β-dehydrogenation of acyl-CoA esters in fatty acid β-oxidation and amino acid catabolism. Genetic defects have been identified in most of the acyl-CoA dehydrogenases in humans. Acyl-CoA dehydrogenase 9 (ACAD9) is a recently identified acyl-CoA dehydrogenase that demonstrates maximum activity with unsaturated long-chain acyl-CoAs. We now report three cases of ACAD9 deficiency. Patient 1 was a 14-year-old, previously healthy boy who died of a Reye-like episode and cerebellar stroke triggered by a mild viral illness and ingestion of aspirin. Patient 2 was a 10-year-old girl who first presented at age 4 mo with recurrent episodes of acute liver dysfunction and hypoglycemia, with otherwise minor illnesses. Patient 3 was a 4.5-year-old girl who died of cardiomyopathy and whose sibling also died of cardiomyopathy at age 21 mo. Mild chronic neurologic dysfunction was reported in all three patients. Defects in ACAD9 mRNA were identified in the first two patients, and all patients manifested marked defects in ACAD9 protein. Despite a significant overlap of substrate specificity, it appears that ACAD9 and very-long-chain acyl-CoA dehydrogenase are unable to compensate for each other in patients with either deficiency. Studies of the tissue distribution and gene regulation of ACAD9 and very-long-chain acyl-CoA dehydrogenase identify the presence of two independently regulated functional pathways for long-chain fat metabolism, indicating that these two enzymes are likely to be involved in different physiological functions.

AB - The acyl-CoA dehydrogenases are a family of multimeric flavoenzymes that catalyze the α,β-dehydrogenation of acyl-CoA esters in fatty acid β-oxidation and amino acid catabolism. Genetic defects have been identified in most of the acyl-CoA dehydrogenases in humans. Acyl-CoA dehydrogenase 9 (ACAD9) is a recently identified acyl-CoA dehydrogenase that demonstrates maximum activity with unsaturated long-chain acyl-CoAs. We now report three cases of ACAD9 deficiency. Patient 1 was a 14-year-old, previously healthy boy who died of a Reye-like episode and cerebellar stroke triggered by a mild viral illness and ingestion of aspirin. Patient 2 was a 10-year-old girl who first presented at age 4 mo with recurrent episodes of acute liver dysfunction and hypoglycemia, with otherwise minor illnesses. Patient 3 was a 4.5-year-old girl who died of cardiomyopathy and whose sibling also died of cardiomyopathy at age 21 mo. Mild chronic neurologic dysfunction was reported in all three patients. Defects in ACAD9 mRNA were identified in the first two patients, and all patients manifested marked defects in ACAD9 protein. Despite a significant overlap of substrate specificity, it appears that ACAD9 and very-long-chain acyl-CoA dehydrogenase are unable to compensate for each other in patients with either deficiency. Studies of the tissue distribution and gene regulation of ACAD9 and very-long-chain acyl-CoA dehydrogenase identify the presence of two independently regulated functional pathways for long-chain fat metabolism, indicating that these two enzymes are likely to be involved in different physiological functions.

UR - http://www.scopus.com/inward/record.url?scp=34347257475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347257475&partnerID=8YFLogxK

U2 - 10.1086/519219

DO - 10.1086/519219

M3 - Article

C2 - 17564966

AN - SCOPUS:34347257475

VL - 81

SP - 87

EP - 103

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 1

ER -